Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: The results of a pilot study

Cephalalgia

Volumn 31, Issue 5, 2011, Pages 543-549

  Caproni, Stefano ^a,b   Corbelli, Ilenia ^a,b   Pini, Luigi Alberto ^c   Cupini, Maria Letizia ^d   Calabresi, Paolo ^a,b   Sarchielli, Paola ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b European Brain Research Institute   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d S Eugenio Hospital   (Italy)

Author keywords

amytryptiline; Flunarizine; migraine; neuropeptide Y; orexin

Indexed keywords

AMITRIPTYLINE; FLUNARIZINE; NEUROPEPTIDE Y; OREXIN A; OREXIN B;

ADULT; ARTICLE; BODY MASS; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; FEMALE; HUMAN; MALE; MIGRAINE; PILOT STUDY; PROTEIN BLOOD LEVEL; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ADULT; AMITRIPTYLINE; ANALGESICS, NON-NARCOTIC; FEMALE; FLUNARIZINE; HUMANS; HYPOTHALAMUS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NEUROPEPTIDES; PILOT PROJECTS; RADIOIMMUNOASSAY; WEIGHT GAIN; YOUNG ADULT;

EID: 79953184308     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102410392605     Document Type: Article

References (37)

1. Taylor FR Weight change associated with the use of migraine-preventive medications. Clin Ther 2008 ; 30: 1069-1080. (Pubitemid 351978119)
2. Young WB and Rozen TD Preventive treatment of migraine: effect on weight. Cephalalgia 2005 ; 25: 1-11. (Pubitemid 40143786)
3. Galletti F., Cupini LM, Corbelli I., Calabresi P. and Sarchielli P. Pathophysiological basis of migraine prophylaxis. Prog Neurobiol 2009 ; 89: 176-192.
4. Maggioni F., Ruffatti S., Dainese F., Mainardi F. and Zanchin G. Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. J Headache Pain 2005 ; 6: 322-324. (Pubitemid 41349339)
5. Dodick DW, Freitag F., Banks J., Saper J., Xiang J., Rupnow M., et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009 ; 31: 542-559.
6. Bigal ME, Lipton RB, Biondi DM, Xiang J. and Hulihan J. Weight change and clinical markers of cardiovascular disease risk during preventive treatment of migraine. Cephalalgia 2009 ; 29: 1188-1196.
7. Gawel MJ, Kreeft J., Nelson RF, Simard D. and Arnott WS Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci 1992 ; 19: 340-345.
8. Berilgen MS, Bulut S., Gonen M., Tekatas A., Dag E. and Mungen B. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005 ; 25: 1048-1053. (Pubitemid 41532110)
9. Hirfanoglu T., Serdaroglu A., Gulbahar O. and Cansu A. Prophylactic drugs and cytokine and leptin levels in children with migraine. Pediatr Neurol 2009 ; 41: 281-287.
10. Kalra SP, Dube MG, Pu S., Xu B., Horvarth TL and Kalra PS Interacting appetite-regulation pathways in the hypothalamic regulation of body weight. Endocr Rev 1999 ; 20: 68-100. (Pubitemid 29092036)
11. Burdakov D. and Antonio González J. Physiological functions of glucose-inhibited neurons. Acta Physiol (Oxf) 2008 ; 195: 71-78.
12. Muroya S., Funahashi H., Yamanaka A., Kohno D., Uramura K., Nambu T., et al. Orexins (hypocretins) directly interact with neuropeptide Y, POMC and glucose-responsive neurons to regulate Ca2+ signaling in a reciprocal manner to leptin: orexigenic neuronal pathways in the mediobasal hypothalamus. Eur J Neurosci 2004 ; 19: 1524-1534. (Pubitemid 38437915)
13. Wang JH, Wang F., Yang MJ, Yu DF, Wu WN, Liu J., et al. Leptin regulated calcium channels of neuropeptide Y and proopiomelanocortin neurons by activation of different signal pathways. Neuroscience 2008 ; 156: 89-98.
14. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain, 2nd edition - 1st Revision ICHD-IIR1. Cephalalgia 2004 ; 24 (Suppl 1): 9-160.
15. Golden J., Conroy RM and O'Dwyer AM Reliability and validity of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory (Full and FastScreen scales) in detecting depression in persons with hepatitis C. J Affect Disord 2007 ; 100: 265-269. (Pubitemid 46818445)
16. Haynes AC, Jackson B., Chapman H., Tadayyon M., Johns A., Porter RA, et al. A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul Pept 2000 ; 96: 45-51.
17. Borgland SL, Storm E. and Bonci A. Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons. Eur J Neurosci 2008 ; 28: 1545-1556.
18. Baird JP, Choe A., Loveland JL, Beck J., Mahoney CE, Lord JS, et al. Orexin-A hyperphagia: hindbrain participation in consummatory feeding responses. Endocrinology 2009 ; 150: 1202-1216.
19. Hinze-Selch D., Schuld A., Kraus T., Kühn M., Uhr M., Haack M., et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000 ; 23: 13-19. (Pubitemid 30408308)
20. Rainero I., Limone P., Ferrero M., Valfrè W., Pelissetto C., Rubino E., et al. Insulin sensitivity is impaired in patients with migraine. Cephalalgia 2005 ; 25: 593-597. (Pubitemid 41026024)
21. Tsuneki H., Wada T. and Sasaoka T. Role of orexin in the regulation of glucose homeostasis. Acta Physiol (Oxf) 2010 ; 198 (3). 335-348.
22. Baranowska B., Woliñska-Witort E., Martyñska L., Chmielowska M. and Baranowska-Bik A. Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women. Neuroendocrinol Lett 2005 ; 26: 293-296. (Pubitemid 41518763)
23. Bronsky J., Nedvídková J., Zamrazilová H., Pechová M., Chada M., Kotaska K., et al. Dynamic changes of orexin A and leptin in obese children during body weight reduction. Physiol Res 2007 ; 56: 89-96.
24. Sarchielli P., Rainero I., Coppola F., Rossi C., Mancini M., Pinessi L., et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia 2008 ; 23: 714-722. (Pubitemid 351799744)
25. Holland P. and Goadsby PJ The hypothalamic orexinergic system: pain and primary headaches. Headache 2007 ; 47: 951-962. (Pubitemid 46944378)
26. Pareja-Angel J. and Campo-Arias A. The prevalence of symptoms of anxiety and depression in female migraine sufferers. Rev Neurol 2004 ; 39: 711-714. (Pubitemid 40568304)
27. Gallai V., Sarchielli P., Trequattrini A., Paciaroni M., Usai F. and Palumbo R. Neuropeptide Y in juvenile migraine and tension-type headache. Headache 1994 ; 34: 35-40. (Pubitemid 24038973)
28. Campbell RE, French-Mullen JM, Cowley MA, Smith MS and Grove KL Hypothalamic circuitry of neuropeptide Y regulation of neuroendocrine function and food intake via the Y5 receptor subtype. Neuroendocrinology 2001 ; 74: 106-119. (Pubitemid 32727577)
29. Kesterson RA, Huszar D., Lynch CA, Simerly RB and Cone RD Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. Mol Endocrinol 1997 ; 11: 630-637. (Pubitemid 27193798)
30. Zarjevski N., Cusin I., Vettor R., Rohner-Jeanrenaud F. and Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993 ; 133: 1753-1758. (Pubitemid 23295205)
31. Masaki T. and Yoshimatsu H. The hypothalamic H1 receptor: a novel therapeutic target for disrupting feeding rhythm and obesity. Trends Pharmacol Sci 2006 ; 27: 279-284.
32. Kohno D., Gao HZ, Muroya S., Kikuyama S. and Yada T. Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes 2003 ; 52: 948-956. (Pubitemid 36384265)
33. Alberto CO, Trask RB, Quinlan ME and Hirasawa M. Bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons. J Neurosci 2006 ; 26: 1043-1050.
34. Ramadan NM Current trends in migraine prophylaxis. Headache 2007 ; 47: S52 - S57.
35. Bigal ME and Lipton RB Putative mechanisms of the relationship between obesity and migraine progression. Curr Pain Headache Rep 2008 ; 12: 207-212.
36. Guldiken B., Guldiken S., Demir M., Turgut N., Kabayel L., Ozkan H., et al. Insulin resistance and high sensitivity C-reactive protein in migraine. Can J Neurol Sci 2008 ; 35: 448-451.
37. Guldiken B., Guldiken S., Taskiran B., Koc G., Turgut N., Kabayel L., et al. Migraine in metabolic syndrome. Neurologist 2009 ; 15: 55-58.